KSPWFTTL (TFA)

• UNSPSC Description:

  KSPWFTTL TFA is an immunodominant Kb-restricted epitope from the p15E transmembrane protein. KSPWFTTL TFA can restore susceptibility of a tumor line to anti-AKR/Gross MuLV cytotoxic T lymphocytes[1][2].

• Target Antigen:

  Others

• Type:

  Peptides

• Related Pathways:

  Others

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Cancer; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/kspwfttl-tfa.html

• Purity:

  99.07

• Solubility:

  H2O : 66.67 mg/mL (ultrasonic)

• Smiles:

  O=C([C@H]1N(CCC1)C([C@H](CO)NC([C@@H](N)CCCCN)=O)=O)N[C@H](C(N[C@H](C(N[C@@H]([C@H](O)C)C(N[C@@H]([C@H](O)C)C(N[C@H](C(O)=O)CC(C)C)=O)=O)=O)CC2=CC=CC=C2)=O)CC3=CNC4=CC=CC=C34.O=C(O)C(F)(F)F

• Molecular Weight:

  1093.15

• References & Citations:

  [1]White HD, et, al. An immunodominant Kb-restricted peptide from the p15E transmembrane protein of endogenous ecotropic murine leukemia virus (MuLV) AKR623 that restores susceptibility of a tumor line to anti-AKR/Gross MuLV cytotoxic T lymphocytes. J Virol. 1994 Feb;68(2):897-904.|[2]Rich RF, et, al. Antiretroviral cytolytic T-lymphocyte nonresponsiveness: FasL/Fas-mediated inhibition of CD4(+) and CD8(+) antiviral T cells by viral antigen-positive veto cells. J Virol. 1999 May;73(5):3826-34.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

• Clinical Information:

  No Development Reported